Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Loxoprofen. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 known ✓ | P23219 | 17/20 | 0.95 |
| ▸ | PTGS2 known ✓ | P35354 | 17/20 | 0.95 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.95 |
| ▸ | HTT | P42858 | 1/20 | 0.95 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.95 |
| ▸ | MT-CO1 | P00395 | 1/20 | 0.56 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Loxoprofen SCHEMBL16166442 | 1.00 | PTGS1 (0.95) | PTGS1PTGS2OPRK1HTTKMT2A | |
| Loxoprofen SCHEMBL28213966 | 0.99 | PTGS1 (0.97) | PTGS1PTGS2OPRK1HTTKMT2A | |
| Loxoprofen SCHEMBL33007 | 0.99 | PTGS1 (0.97) | PTGS1PTGS2OPRK1HTTKMT2A | |
| Loxoprofen SCHEMBL11133884 | 0.97 | PTGS1 (1.00) | PTGS1PTGS2OPRK1HTTKMT2A | |
| Loxoprofen SCHEMBL24423 | 0.97 | PTGS1 (1.00) | PTGS1PTGS2OPRK1HTTKMT2A | |
| Loxoprofen SCHEMBL28914090 | 0.97 | PTGS1 (1.00) | PTGS1PTGS2OPRK1HTTKMT2A | |
| Loxoprofen SCHEMBL14312087 | 0.97 | PTGS1 (1.00) | PTGS1PTGS2OPRK1HTTKMT2A | |
| Loxoprofen SCHEMBL28562194 | 0.97 | PTGS1 (1.00) | PTGS1PTGS2OPRK1HTTKMT2A | |
| Loxoprofen SCHEMBL28914092 | 0.97 | PTGS1 (1.00) | PTGS1PTGS2OPRK1HTTKMT2A | |
| Loxoprofen SCHEMBL28562193 | 0.97 | PTGS1 (1.00) | PTGS1PTGS2OPRK1HTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 140 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260137632-A1 | NONAQUEOUS PREPARATION FOR PERCUTANEOUS ABSORPTION | LEAD CHEMICAL CO., LTD. (JP) | 2026-05-21 | — | — | US | claimed |
| EP-4656206-A1 | NON-AQUEOUS PERCUTANEOUSLY ABSORPTIVE FORMULATION | Lead Chemical Co., Ltd. (JP) | 2025-12-03 | — | — | EP | claimed |
| US-20250332120-A1 | COMPOSITION FOR EXTERNAL PREPARATION | KAO CORPORATION (JP) | 2025-10-30 | — | — | US | claimed |
| CN-120035451-A | Nonaqueous percutaneous absorption preparation | 立德化学株式会社 | 2025-05-23 | — | — | CN | claimed |
| CN-119185218-A | Preparation method of loxoprofen sodium tablet | 北京云鹏鹏程医药科技有限公司 | 2024-12-27 | — | — | CN | claimed |
| WO-2024157473-A1 | NON-AQUEOUS PERCUTANEOUSLY ABSORPTIVE FORMULATION | リードケミカル株式会社 | 2024-08-02 | — | — | WO | claimed |
| EP-2543366-B1 | FILM PREPARATION CONTAINING MEDICAMENT WITH UNPLEASANT TASTE | KYUKYU YAKUHIN KOGYO KK (JP) | 2018-10-24 | — | — | EP | claimed |
| US-20170151177-A1 | LOXOPROFEN AND GAMMA-AMINOBUTIRIC ACID RECEPTOR AGONIST COMBINATIONS | SANOVEL ILAC SANAYI VE TICARET ANONIM SIRKETI (TR) | 2017-06-01 | — | — | US | claimed |
| WO-2015165847-A1 | PHARMACEUTICAL FORMULATIONS OF LOXOPROFEN | SANOVEL ILAC SANAYI VE TICARET A.S. (TR) | 2015-11-05 | — | — | WO | claimed |
| EP-2939666-A1 | PHARMACEUTICAL FORMULATIONS OF LOXOPROFEN | Sanovel Ilac Sanayi ve Ticaret A.S. (TR) | 2015-11-04 | — | — | EP | claimed |
| EP-2926832-A1 | PHARMACEUTICAL FORMULATIONS OF LOXOPROFEN FOR TOPICAL USE | Sanovel Ilac Sanayi ve Ticaret A.S. (TR) | 2015-10-07 | — | — | EP | claimed |
| CN-102740854-A | Loxoprofen-containing pharmaceutical composition | KOWA CO | 2012-10-17 | — | — | CN | claimed |
| US-20260137632-A1 | NONAQUEOUS PREPARATION FOR PERCUTANEOUS ABSORPTION | LEAD CHEMICAL CO., LTD. (JP) | 2026-05-21 | — | — | US | disclosed |
| CN-122031446-A | External pharmaceutical composition containing loxoprofen and felbinac | 第一三共健康事业株式会社 | 2026-05-15 | — | — | CN | disclosed |
| CN-122031445-A | External pharmaceutical composition containing loxoprofen | 第一三共健康事业株式会社 | 2026-05-15 | — | — | CN | disclosed |
| CN-122031449-A | External pharmaceutical composition containing loxoprofen and diclofenac | 第一三共健康事业株式会社 | 2026-05-15 | — | — | CN | disclosed |
| US-20100256238-A1 | EMULSION-TYPE EXTERNAL PREPARATION, AND METHOD FOR PRODUCTION THEREOF | YUTOKU PHARMACEUTICAL INDUSTRIES CO., LTD. (JP) | 2010-10-07 | — | — | US | disclosed |
| JP-2010150250-A | LOXOPROFEN-CONTAINING PHARMACEUTICAL COMPOSITION | KOWA CO | 2010-07-08 | — | — | JP | disclosed |
| JP-2010126476-A | PHARMACEUTICAL COMPOSITION CONTAINING LOXOPROFEN | KOWA CO | 2010-06-10 | — | — | JP | disclosed |
| JP-2010083882-A | LOXOPROFEN-CONTAINING PHARMACEUTICAL COMPOSITION | KOWA CO | 2010-04-15 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170151177-A1 | LOXOPROFEN AND GAMMA-AMINOBUTIRIC ACID RECEPTOR AGONIST COMBINATIONS | PTGIR, ADRB1, PTGER1 | PTGS1 72/4885PTGS2 131/4885OPRK1 67/4885 |
| US-20260137632-A1 | NONAQUEOUS PREPARATION FOR PERCUTANEOUS ABSORPTION | PTGS1, PTGER1, MMP1 | PTGS1 1/4885PTGS2 12/4885OPRK1 121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.